208 related articles for article (PubMed ID: 36414177)
1. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
Kato JY; Korenaga S; Iwakura M
Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
[TBL] [Abstract][Full Text] [Related]
2. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
3. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Chang Y; Xu S; Ding K
J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
[TBL] [Abstract][Full Text] [Related]
6. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
[TBL] [Abstract][Full Text] [Related]
8. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
[TBL] [Abstract][Full Text] [Related]
9. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
10. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
11. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
12. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.
Shah RR; Redmond JM; Mihut A; Menon M; Evans JP; Murphy JA; Bartholomew MA; Coe DM
Bioorg Med Chem; 2020 Mar; 28(5):115326. PubMed ID: 32001089
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
[TBL] [Abstract][Full Text] [Related]
14. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
Chen C; Lu D; Sun T; Zhang T
Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
[TBL] [Abstract][Full Text] [Related]
15. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
16. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
Zhong HA; Almahmoud S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
19. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of Janus kinases.
Pesu M; Laurence A; Kishore N; Zwillich SH; Chan G; O'Shea JJ
Immunol Rev; 2008 Jun; 223():132-42. PubMed ID: 18613833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
